MICHAEL ISAACS: Open Payments
NPI 1588013353 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,249 in 182 payments from 21 companies in 2025. Trend: 2023 $2,469 · 2024 $2,833 · 2025 $3,249
Food & beverage: $3,242Education: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $474 |
| UCB, Inc. | 19 | $440 |
| PFIZER INC. | 23 | $382 |
| Novartis Pharmaceuticals Corporation | 29 | $334 |
| Galderma Laboratories, L.P. | 18 | $269 |
| Regeneron Healthcare Solutions, Inc. | 5 | $202 |
| Lilly USA, LLC | 9 | $187 |
| Arcutis Biotherapeutics, Inc. | 8 | $185 |
| E.R. Squibb & Sons, L.L.C. | 9 | $158 |
| Incyte Corporation | 8 | $142 |
Products named: Bimzelx, CIBINQO, RINVOQ, NEMLUVIO, SKYRIZI, TALTZ, Zoryve, COSENTYX.
Industry payments across IN — which companies pay providers there.
